Paloron ODT 0.5 mg (Dispersible Tablet)

Indications

• Acute and delayed nausea and vomiting
• Uncontrolled nausea and vomiting
• Chemotherapy-induced nausea and vomiting (CINV)
• Radiotherapy-induced nausea and vomiting (RINV)
• Post-operative & Post-discharge nausea and vomiting (PONV & PDNV)

Pharmacology

• 5-HT3 receptor antagonist
• Strong binding affinity for 5-HT3 receptor
• Little or no affinity for other receptors
• Works by blocking the actions of Serotonin at 5-HT3 receptor
• Exhibits linear dose-proportional pharmacokinetics
• Metabolized via kidney and liver CYP enzymes

Dosage & Administration

• Adult tablet dosage: 0.5 mg daily
• Adult IV dosage: 0.075 mg over 10 seconds
• Administered approximately 1 hour prior to chemotherapy
• Children dosage: Single IV dose at 20 mcg/kg body weight

Interaction

• Safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents
• No significant pharmacokinetic interactions with metoclopramide
• Not inhibitor or inducer of major CYP enzymes

Contraindications

• Hypersensitivity to the drug or any of its components

Side Effects

• Headaches
• Constipation

Pregnancy & Lactation

• Pregnancy category 'B'
• Not known whether excreted in breast milk

Use in Special Populations

• No dosage adjustment in elderly patients
• No dosage adjustment in patients with renal and hepatic dysfunction

Overdose Effects

• No known antidote
• Managed with supportive care

Therapeutic Class

• Anti-emetic drugs

Storage Conditions

• Store in a cool & dry place, protected from light

Related Brands

• Vomiren 0.5 mg (Tablet) - renata-limited
• Vomiren 0.075 mg/1.5 ml (IV Injection) - renata-limited
• Vomiren 0.25 mg/5 ml (IV Injection) - renata-limited